Stratagene, Pfizer, Genta

Feb 08, 2007

Premium

Stratagene Licenses miRNA Sequences for Dx Development

Stratagene said this week that it has acquired a license to more than 150 microRNA sequences from the Max Planck Society.

Under the terms of the deal, Stratagene will have the right to use the sequences for the development, manufacture, and sale of molecular diagnostic kits.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Building Up Numbers

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Slow Coverage

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

Many Choices

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

This Week in Nature

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.

Featured White Papers

Can Saliva Replace Blood for DNA Collection and Analysis?

Best Practices for RNA Transcriptome Sequencing

Tissue Section Imaging

In Vivo Validation of Optical Probes

Aug

07

Featured Webinar

Rapid and Comprehensive NGS Variant Interpretation Using Web-Based Software

This webinar will present the results of an evaluation of a web-based variant interpretation software system for clinical next-generation sequencing.

Main menu